BioCryst Pharmaceuticals Inc. (BCRX)
NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BCRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.86B
- Forward P/E
- 8.44
- EPS (TTM)
- -$1.28
- Dividend yield
- None
- 52-week range
- 6.23 – 11.22
- Day range
- 7.15 – 7.39
- Volume / Avg
- 3.85M / 4.97M
- Beta
- —
- Shares outstanding
- 257.30M
52-week range
BCRX stock today
On Nov 20, BCRX ended the session at $7.22, shedding $0.10 (1.37%), versus the S&P 500's 3.70% decline. Shares are 35.7% below their 52-week high of $11.22, set on Jul 9, 2026 and 15.9% above the 52-week low of $6.23, near the bottom of the past year's range. BCRX is down 7.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 3.6%.
BioCryst Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.28), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About BioCryst Pharmaceuticals
Company profileBioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Charles K. Gayer
- Headquarters
- Durham, NC
- Employees
- 435
- IPO year
- 1994
- Website
- biocryst.com
Financial highlights
Full financialsIn fiscal 2025, BioCryst Pharmaceuticals generated $874.8 million in revenue, up 94.1% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $263.9 million, for a net margin of 30.2% versus a median of -91.2% in the prior 5 years. Gross margin was 97.8% (up from 97.3%) and operating margin 39.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $874.84M | $450.71M | $331.41M | $270.83M | $157.17M |
| Growth | +94.10% | +36.00% | +22.37% | +72.31% | +782.38% |
| Net income | $263.86M | $-88.88M | $-226.54M | $-247.12M | $-184.06M |
| EPS (diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
Analyst forecast
ForecastConsensus (11 analysts)
buy
Avg. price target
$20.45+183.24%
- Strong buy 2
- Buy 7
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.06 vs $0.10
- Surprise
- -40.00%
BCRX news
All BCRX news- BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific MeetingGlobeNewswire
- The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and MadrigalNasdaqBCRX, INSM, TGTX, MDGL
- 4 Commercial-Stage Biotechs Poised for Sustained Revenue GrowthNasdaqBCRX, INSM, TGTX, MDGL
- BioCryst to Present at Upcoming Investor ConferencesGlobeNewswire
- BioCryst (BCRX) Q3 2026 Earnings Call TranscriptNasdaq
- BioCryst Reports Third Quarter 2026 Financial ResultsNasdaq
- BioCryst Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- BioCryst to Report Third Quarter 2026 Financial Results on November 4GlobeNewswire
BioCryst Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| COAGHemab Therapeutics Holdings Inc. | 39.29 | -1.43% | $1.84B | vs BCRX |
| REPLReplimune Group Inc. | 19.07 | -0.83% | $1.81B | vs BCRX |
| LYCALycia Therapeutics Inc. | 33.07 | +4.09% | $1.72B | vs BCRX |
| MAZEMaze Therapeutics Inc. | 31.37 | -3.27% | $1.72B | vs BCRX |
| BEAMBeam Therapeutics Inc. | 20.90 | -0.19% | $2.16B | vs BCRX |
| VIRVir Biotechnology Inc. | 8.39 | -5.41% | $1.56B | vs BCRX |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs BCRX |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs BCRX |
Indexes, lists and sector
BioCryst Pharmaceuticals stock FAQ
What is BioCryst Pharmaceuticals's stock price today?
BCRX last traded at $7.22 as of Nov 20, 4:00 PM EST, down 1.37% on the day. Prices are delayed at least 15 minutes.
Who is BioCryst Pharmaceuticals's CEO?
Mr. Charles K. Gayer is the chief executive officer of BioCryst Pharmaceuticals Inc., which has about 435 employees.
What is the BCRX 52-week high?
The 52-week high for BCRX is $11.22 and the 52-week low is $6.23. The stock is currently 35.7% below its high.